Skip to main content
eScholarship
Open Access Publications from the University of California

Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes

  • Author(s): Polyzos, A
  • Holt, A
  • Brown, C
  • Cosme, C
  • Wipf, P
  • Gomez-Marin, A
  • Castro, MR
  • Ayala-Peña, S
  • McMurray, CT
  • et al.

Published Web Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986333/
No data is associated with this publication.
Abstract

Oxidative damage to mitochondria (MT) is a major mechanism for aging and neurodegeneration. We have developed a novel synthetic antioxidant, XJB-5-131, which directly targets MT, the primary site and primary target of oxidative damage. XJB-5-131 prevents the onset of motor decline in an HdhQ(150/150) mouse model for Huntington's disease (HD) if treatment starts early. Here, we report that XJB-5-131 attenuates or reverses disease progression if treatment occurs after disease onset. In animals with well-developed pathology, XJB-5-131 promotes weight gain, prevents neuronal death, reduces oxidative damage in neurons, suppresses the decline of motor performance or improves it, and reduces a graying phenotype in treated HdhQ(150/150) animals relative to matched littermate controls. XJB-5-131 holds promise as a clinical candidate for the treatment of HD.

Item not freely available? Link broken?
Report a problem accessing this item